Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted

Name: Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted
Published: 2019
License: Public Domain

Jonsson Comprehensive Cancer Center · 2019

ClinicalTrials.gov · Datasets · License: Public Domain · 2019

Open Source ↗

anatomic stage 0 breast cancer ajcc v8, anatomic stage i breast cancer ajcc v8, anatomic stage ia breast cancer ajcc v8, anatomic stage ib breast cancer ajcc v8, anatomic stage ii breast cancer ajcc v8, anatomic stage iia breast cancer ajcc v8, anatomic stage iib breast cancer ajcc v8, anatomic stage iiia breast cancer ajcc v8, anatomic stage iiib breast cancer ajcc v8, her2/neu negative, invasive ductal carcinoma, not otherwise specified, progesterone receptor negative

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 812914
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.